Skip to main content

Table 13 Summary of findings table for treatment with erenumab 70 mg monthly subcutaneous injection compared with no treatment for prevention of chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Outcomes Anticipated absolute effects*(95% CI) Relative effect(95% CI) № of participants (studies) Certainty of the evidence(GRADE) Comments
Risk with placebo Risk with erenumab
Reduction of monthly migraine days follow up: 3 months The mean reduction of monthly migraine days was − 4.2 days The mean reduction of monthly migraine days in the intervention group was 2.5 days fewer (3.5 lower to 1.4 fewer) 469(1 RCT) MEDIUMa Treatment with Erenumab 70 mg reduces monthly migraine days slightly compared to placebo.
Reduction of monthly acute treatment daysfollow up: 3 months The mean reduction of monthly acute treatment days was −1.6 days The mean reduction of monthly acute treatment days in the intervention group was 1.9 days fewer (2.6 fewer to 1.1 fewer) 469(1 RCT) MEDIUMa Treatment with Erenumab 70 mg reduces monthly acute treatment days slightly compared to placebo.
At least 50% reduction of monthly migraine days follow up: 3 months 235 per 1000 399 per 1000(303 to 525) RR 1.6985 (1.2908 to 2.2349) 469(1 RCT) MEDIUMa Treatment with Erenumab 70 mg results in at least 50% reduction of monthly migraine days compared to placebo.
Serious adverse events follow up: 3 months 25 per 1000 31 per 1000(11 to 92) RR 1.2722(0.4340 to 3.7268) 471(1 RCT) MEDIUMa Treatment with Erenumab 70 mg results in a small unimportant increase of serious adverse event occurrence compared to placebo.
Mortalityfollow up: 3 months 0 per 1000 0 per 1000(0 to 0) not estimable 471(1 RCT)   No deaths were observed with treatment with Erenumab 70 mg or placebo
  1. CI: Confidence interval; RR: Risk ratio; RCT: randomized controlled trial; aDowngraded once due to imprecision: phase II study
  2. GRADE Working Group grades of evidenceHigh certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect